tegafurgimeraciloteracil sold brand name teysuno among others fixeddose combination medication used treatment advanced gastric cancer used combination also treatment head neck cancer colorectal cancer lung breast pancreatic biliary tract common severe side effects used combination cisplatin include neutropenia low levels neutrophils type white blood cell anaemia low red blood cell counts fatigue tegafurgimeraciloteracil teysuno approved medical use european union march european union tegafurgimeraciloteracil indicated treatment advanced gastric cancer given combination european union tegafurgimeraciloteracil must used following groups tegafur chemotherapeutic agent prodrug active substance fluorouracil tegafur cytotoxic medicine medicine kills rapidly dividing cells cancer cells belongs antimetabolites group tegafur converted medicine fluorouracil body converted tumor cells normal fluorouracil similar pyrimidine part genetic material cells dna body fluorouracil takes place pyrimidine interferes enzymes involved making new result prevents growth tumor cells eventually kills gimeracil inhibits degradation fluorouracil reversibly blocking dehydrogenase enzyme dihydropyrimidine dehydrogenase dpd results higher levels prolonged halflife oteracil mainly stays gut low permeability reduces production blocking enzyme orotate phosphoribosyltransferase lower levels gut result lower gastrointestinal within medication molar ratio three components tegafurgimeraciloteracil developed treatment hepatocellular activity esophagealperry chapter breastcitation needed cervicalcitation needed colorectal tegafur gimeracil oteracil potassium httpsenwikipediaorgwikitegafurgimeraciloteracil